Phase I/II Deep Tumor + Radiotherapy

Authors: Myerson RJ, Scott CB, Emami B, Sapozink MD, Samulski TV.
Publication: Int J Hyperthermia. 1996 Jul-Aug;12(4):449-59.

PURPOSE:
The purpose of this paper is to evaluate the safety and efficacy of deep hyperthermia in conjunction with radiation therapy.

Phase II Soft Tissue Sarcoma + Radiotherapy

Authors: Maguire PD, Samulski TV, Prosnitz LR, Jones EL, Rosner GL, Powers B, Layfield LW, Brizel DM, Scully SP, Harrelson JM, Dewhirst MW.
Publication: Int J Hyperthermia. 2001 Jul-Aug;17(4):283-90.

PURPOSE:
We prospectively evaluated whether delivering a thermal dose of > 10 cumulative equivalent minutes at 43 degrees C to >90% of the tumour sites monitored (CEM43 degrees T90) would produce a pathologic complete response (pCR) in > 75% of high-grade soft tissue sarcomas treated pre-operatively with thermoradiotherapy.

Phase II Cervical + Radiotherapy + Chemotherapy

Authors: Jones EL, Samulski TV, Dewhirst MW, Alvarez-Secord A, Berchuck A, Clarke-Pearson D, Havrilesky LJ, Soper J, Prosnitz LR.
Publication: Cancer. 2003 Jul 15;98(2):277-82.

BACKGROUND:
Five randomized studies have demonstrated a benefit derived from adding cisplatin (CDDP)-based chemotherapy to radiotherapy (RT) for treatment of cervical carcinoma. The Dutch Phase III pelvic tumor trial demonstrated a survival and local control benefit due to the addition of hyperthermia (HT) to RT. The authors evaluated response and toxicity in patients with locally advanced cervical carcinoma (LACC) who were treated with concurrent weekly CDDP, HT, and RT (whole pelvis [n=7] and whole pelvis and paraaortic nodes [n=5]).

Phase II Rectal + Radiotherapy + Chemotherapy

Authors: Anscher MS, Lee C, Hurwitz H, Tyler D, Prosnitz LR, Jowell P, Rosner G, Samulski T, Dewhirst MW.
Publication: Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):719-24.

PURPOSE:
To determine the feasibility of combining external beam radiotherapy, continuous infusion 5-fluorouracil (5-FU), and external microwave hyperthermia in patients with locally advanced, unresectable, or recurrent adenocarcinoma of the rectum.

Phase I/II Soft Tissue Sarcoma + Radiotherapy

Authors: Scully SP, Oleson JR, Leopold KA, Samulski TV, Dodge R, Harrelson JM.
Publication: J Surg Oncol. 1994 Nov;57(3):143-51.

PURPOSE:
In the treatment of soft tissue sarcomas, hyperthermia has been demonstrated to enhance tumor necrosis from radiation therapy. The current study reports the clinical course of patients treated with this neoadjuvant therapy regimen.

Phase II Prostate + Radiotherapy

Authors: Anscher MS, Samulski TV, Dodge R, Prosnitz LR, Dewhirst MW.
Publication: Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1059-65.

PURPOSE:
To determine the safety and efficacy of combined external beam irradiation and external regional hyperthermia in the treatment of adenocarcinoma of the prostate.

Phase III Bladder/Cervical/Rectal + Radiotherapy

Authors: van der Zee J, González González D, van Rhoon GC, van Dijk JD, van Putten WL, Hart AA.
Publication: Lancet. 2000 Apr 1;355(9210):1119-25.

BACKGROUND:
Local-control rates after radiotherapy for locally advanced tumours of the bladder, cervix, and rectum are disappointing. We investigated the effect of adding hyperthermia to standard radiotherapy.

Phase II Vaginal + Radiotherapy

Authors: Aktas M, de Jong D, Nuyttens JJ, van der Zee J, Wielheesen DH, Batman E, Burger CW, Ansink AC.
Publication: Eur J Obstet Gynecol Reprod Biol. 2007 Jul;133(1):100-4. Epub 2006 Jun 13.

OBJECTIVE:
To evaluate the supplementary value of adding hyperthermia to radiotherapy in patients with primary vaginal cancer.

Abstract: Concomitant radiotherapy and hyperthermia for primary carcinoma of the vagina: A cohort study

Objective

To evaluate the supplementary value of adding hyperthermia to radiotherapy in patients with primary vaginal cancer.

Study design

Cohort of 44 patients diagnosed with primary vaginal cancer between 1990 and 2002 was assessed. Survival rates and median survival of patients with primary vaginal cancer undergoing radiotherapy with and without hyperthermia were compared. Hyperthermia was solely added to radiotherapy in case of a tumor size >4 cm in diameter for FIGO stage III disease.

Results

The calculated overall 5-year survival of primary vaginal cancer was 63%. In comparison to histologic high grade tumors, higher survival rates for histologic low grade tumors were calculated. For FIGO stage III of disease, the addition of hyperthermia to radiotherapy for tumors >4 cm in diameter resulted similar survival rates and median survival when compared to those achieved by radiotherapy as monotherapy in tumors of <4 cm in diameter.

Conclusions

The addition of hyperthermia to radiotherapy might result in better survival rates in primary vaginal cancer for tumors >4 cm in diameter. The supplementary effect of hyperthermia to radiotherapy may be a feasible and beneficial approach in the treatment of vaginal cancer.

Authors

Aktas M, de Jong D, Nuyttens JJ, van der Zee J, Wielheesen DHM, Batman E, Burger CW, Ansink AC.

Study Link

Concomitant radiotherapy and hyperthermia for primary carcinoma of the vagina: A cohort study.
European Journal of Obstetrics & Gynecology and Reproductive Biology 2007;133(1):100-4.

{module=348}

Phase II Prostate + Radiotherapy + Androgen Suppression Therapy

Authors: Maluta S, Dall'Oglio S, Romano M, Marciai N, Pioli F, Giri MG, Benecchi PL, Comunale L, Porcaro AB
Publication: Int J Hyperthermia. 2007 Aug;23(5):451-6.

PURPOSE:
Hyperthermia has been used in several trials to treat pelvic cancers without excessive toxicity and with positive results. The aim of this study was to evaluate feasibility and results in terms of biochemical recurrence-free, disease-free survival, overall survival, and treatment toxicity profile of hyperthermia combined with radiotherapy in locally advanced high risk prostate cancer.

Phase II Pelvic + Radiotherapy

Authors: Feldmann HJ, Molls M, Krümplemann S, Stuschke M, Sack H.
Publication: Int J Radiat Oncol Biol Phys. 1993 Apr 30;26(1):111-6.

PURPOSE:
Several institutions have accumulated clinical experience with the annular array as well as with the Sigma applicator. There exist only limited data in comparison of both heating devices possibly favoring the annular array over the Sigma applicator with regard to tumor temperatures and acute toxicity. The objective of this study was to record temperature distributions at identical sites in tumor and normal tissue in the same patients treated with each device.

Phase I/II Prostate + Radiotherapy

Authors: Kalapurakal JA, Pierce M, Chen A, Sathiaseelan V.
Publication: Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):654-64.

PURPOSE:
To present a preliminary report on the feasibility, efficacy, and toxicity of irradiation (RT) and hyperthermia (HT) in patients with locally advanced, hormone-refractory prostate cancer (LAHRPC) who may or may not have received prior RT.

Analysis Rectal + Radiotherapy + Chemotherapy

Authors: Zwirner K, Bonomo 2, Lamprecht U, Zips D, Gani C.
Publication: Int J Hyperthermia. 2018 Jun;34(4):455-460. doi: 10.1080/02656736.2017.1338364. Epub 2017 Jul 26.

PURPOSE:
To validate a nomogram for the prediction of treatment outcomes after preoperative radiochemotherapy and surgery for locally advanced rectal cancer with a cohort of patients treated with additional deep regional hyperthermia.

Phase I/II Cervical + Radiotherapy + Chemotherapy

Authors: Westermann AM, Jones EL, Schem BC, van der Steen-Banasik EM, Koper P, Mella O, Uitterhoeve AL, de Wit R, van der Velden J, Burger C, van der Wilt CL, Dahl O, Prosnitz LR, van der Zee J.
Publication: Cancer. 2005 Aug 15;104(4):763-70.

BACKGROUND:
Patients with advanced cervical carcinoma are treated routinely with radiotherapy and cisplatin-containing chemotherapy. It has been shown that hyperthermia can improve the results of both radiotherapy and cisplatin. In the current study, the feasibility and efficacy of the combination of all three modalities was studied in previously untreated patients with cervical carcinoma.

Phase III Cervical + Radiotherapy

Authors: Franckena M, Stalpers LJ, Koper PC, Wiggenraad RG, Hoogenraad WJ, van Dijk JD, Wárlám-Rodenhuis CC, Jobsen JJ, van Rhoon GC, van der Zee J.
Publication: Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1176-82. Epub 2007 Sep 19.

PURPOSE:
The local failure rate in patients with locoregionally advanced cervical cancer is 41-72% after radiotherapy (RT) alone, whereas local control is a prerequisite for cure. The Dutch Deep Hyperthermia Trial showed that combining RT with hyperthermia (HT) improved 3-year local control rates of 41-61%, as we reported earlier. In this study, we evaluate long-term results of the Dutch Deep Hyperthermia Trial after 12 years of follow-up.

Phase I/II Cervical + Radiotherapy + Chemotherapy

Authors: Westermann A, Mella O, Van Der Zee J, Jones EL, Van Der Steen-Banasik E, Koper P, Uitterhoeve AL, De Wit R, Van Der Velden J, Burger C, Schem BC, Van Der Wilt C, Dahl O, Prosnitz LR, Van Tinteren H.
Publication: Int J Hyperthermia. 2012;28(6):549-53. doi: 10.3109/02656736.2012.673047. Epub 2012 Jul 13.

BACKGROUND:
Advanced cervical cancer is routinely treated with radiotherapy and cisplatin-containing chemotherapy. Hyperthermia has been shown to improve the results of both radiotherapy and cisplatin. The feasibility of the combination of all three modalities was demonstrated and reported in a study of 68 previously untreated cervical cancer patients in 2005. Long-term follow-up is presented here.

Phase III Soft Tisse Sarcoma + Chemotherapy

Authors: Issels RD, Lindner LH, Verweij J, Wust P, Reichardt P, Schem BC, Abdel-Rahman S, Daugaard S, Salat C, Wendtner CM, Vujaskovic Z, Wessalowski R, Jauch KW, Dürr HR, Ploner F, Baur-Melnyk A, Mansmann U, Hiddemann W, Blay JY, Hohenberger P; European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC-STBSG); European Society for Hyperthermic Oncology (ESHO).
Publication: Lancet Oncol. 2010 Jun;11(6):561-70. doi: 10.1016/S1470-2045(10)70071-1. Epub 2010 Apr 29.

BACKGROUND:
The optimum treatment for high-risk soft-tissue sarcoma (STS) in adults is unclear. Regional hyperthermia concentrates the action of chemotherapy within the heated tumour region. Phase 2 studies have shown that chemotherapy with regional hyperthermia improves local control compared with chemotherapy alone. We designed a parallel-group randomised controlled trial to assess the safety and efficacy of regional hyperthermia with chemotherapy.

Analysis Cervical + Radiotherapy + Chemotherapy

Authors: Heijkoop ST, Franckena M, Thomeer MG, Boere IA, Van Montfort C, Van Doorn HC.
Publication: Int J Hyperthermia. 2012;28(6):554-61. doi: 10.3109/02656736.2012.674622. Epub 2012 Jun 12.

OBJECTIVE:
To evaluate the efficacy of neoadjuvant chemotherapy, followed by radiotherapy and concurrent hyperthermia (triple therapy) in patients with advanced-stage cervical cancer.

Analysis Phase III Rectal + Radiotherapy + Chemotherapy

Authors: Schroeder C, Gani C, Lamprecht U, von Weyhern CH, Weinmann M, Bamberg M, Berger B.
Publication: Int J Hyperthermia. 2012;28(8):707-14. doi: 10.3109/02656736.2012.722263. Epub 2012 Sep 24.

PURPOSE:
To evaluate the influence of regional hyperthermia on rates of complete pathological response (pCR) and sphincter-sparing surgery in the context of an up-to-date radiochemotherapy protocol for locally advanced rectal cancer.

Phase I/II Deep Tumors + Radiotherapy

Authors: Myerson RJ, Leybovich L, Emami B, Grigsby PW, Straube W, Von Gerichten D.
Publication: Int J Hyperthermia. 1991 Nov-Dec;7(6):937-51.

PURPOSE:
The BSD 2000 system is an array of microwave antennas operating in the 60-120 MHz range. It is a four-quadrant regional hyperthermia device with phase control permitting the operator to choose the point of constructive interference. A computer preplanning system is provided.